{"id":6535,"date":"2022-08-26T06:00:00","date_gmt":"2022-08-26T06:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\/"},"modified":"2022-08-26T06:00:00","modified_gmt":"2022-08-26T06:00:00","slug":"nanexa-publicerar-delarsrapport-for-januari-juni-2022","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\/","title":{"rendered":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2022"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Pilotanl\u00e4ggningen invigd och GMP-certifierad, patent godk\u00e4nt i Europa och produktprojekten n\u00e4rmar sig klinisk fas<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p><strong>V\u00e4sentliga h\u00e4ndelser under andra kvartalet 2022<\/strong><\/p>\n<ul>\n<li>Europeiska patentverket (EPO) godk\u00e4nde Nanexas patentans\u00f6kan avseende drug delivery-systemet PharmaShell\u00ae. Patentskyddet omfattar metoden f\u00f6r tillverkning av PharmaShell och produkter tillverkade genom metoden.<\/li>\n<li>Nanexa beviljades medel inom ramen f\u00f6r VINNOVA-projektet \u201dVerifiering i Testa Center, del III\u201d till ett belopp p\u00e5 maximalt 290 000 kronor, f\u00f6r ett internt forskningsprojekt med m\u00e5let att bel\u00e4gga monoklonala antikroppar (mAbs) med PharmaShell.<\/li>\n<li>Nanexa f\u00e4rdigst\u00e4llde nya lokaler med kontor, R&amp;D-laboratorie och pilotanl\u00e4ggning f\u00f6r produktion i Uppsala Business Park och en invigning h\u00f6lls den 9 juni.<\/li>\n<li>L\u00e4kemedelsverket genomf\u00f6rde en inspektion av den nya pilotanl\u00e4ggningen f\u00f6r att utf\u00e4rda GMP-certifikat f\u00f6r tillverkning av kliniskt pr\u00f6vningsmaterial. Inspektionen genomf\u00f6rdes utan st\u00f6rre anm\u00e4rkningar.<\/li>\n<li>Vid Nanexas \u00e5rsst\u00e4mma den 9 juni beslutades bl a att v\u00e4lja Richard Davis till ny styrelseledamot, om bemyndiganden f\u00f6r styrelsen att besluta om f\u00f6retr\u00e4desemission respektive riktad emission, samt att inr\u00e4tta ett teckningsoptionsbaserat incitamentsprogram f\u00f6r anst\u00e4llda. Totalt tecknades d\u00e4refter 983 000 teckningsoptioner, motsvarande en maximal utsp\u00e4dning om 1,9%.<\/li>\n<\/ul>\n<p><strong>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/strong><\/p>\n<ul>\n<li>Nanexa ut\u00f6kade sitt samarbetsavtal med Applied Materials, Inc. genom ett till\u00e4ggsavtal som reglerar kommersiella fr\u00e5gor och banar v\u00e4g f\u00f6r potentiella framtida licensavtal med kunder inom l\u00e4kemedelsbranschen.<\/li>\n<li>Nanexa erh\u00f6ll ut\u00f6kat GMP-certifikat fr\u00e5n L\u00e4kemedelsverket f\u00f6r tillverkning och frisl\u00e4ppning av kliniskt pr\u00f6vningsmaterial i den nya pilotanl\u00e4ggningen i Uppsala, baserat p\u00e5 den inspektion som genomf\u00f6rdes under andra kvartalet.<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 april \u2013 30 juni 2022<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 211 (342) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -15 854 (-8 296) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -16 224 (-8 339) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,32 (-0,33) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -20 822 (-6 253) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 66 904 (28 596) kSEK<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 januari \u2013 30 juni 2022<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 509 (878) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -28 185 (-14 919) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -28 594 (-15 008) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,56 (-0,64) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -38 756 (15 905) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 66 904 (28 596) kSEK<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 bolagets hemsida via f\u00f6ljande l\u00e4nk, <a href=\"https:\/\/nanexa.com\/finansiella-rapporter\/\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/nanexa.com\/finansiella-rapporter\/<\/a>.<\/p>\n<p><strong>Rapportkommentar 26 augusti kl 10:00<\/strong><\/p>\n<p>En lives\u00e4nd Rapportkommentar h\u00e5lls p\u00e5 Infront Direkt Studios kl 10:00, d\u00e4r vd David Westberg svarar p\u00e5 fr\u00e5gor fr\u00e5n reporter och tittarna ges m\u00f6jlighet att st\u00e4lla fr\u00e5gor via chat.<\/p>\n<p>S\u00e4ndningen kan ses p\u00e5 <a href=\"https:\/\/www.youtube.com\/watch?v=T76wpbdAq8k\" target=\"_blank\" rel=\"nofollow noopener\">denna l\u00e4nk<\/a>.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" target=\"_blank\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" target=\"_blank\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar parenterala l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2022-08-26 08:00 CEST.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/061ac81b-b6db-4da3-9da6-51588cc43647\/nanexa-delarsrapport-jan-jun-2022.pdf\" target=\"_blank\" rel=\"nofollow noopener\">Nanexa Del\u00e5rsrapport Jan Jun 2022<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pilotanl\u00e4ggningen invigd och GMP-certifierad, patent godk\u00e4nt i Europa och produktprojekten n\u00e4rmar sig klinisk fas<\/p>\n","protected":false},"template":"","class_list":["post-6535","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report-interim-q2_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2022 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2022 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Pilotanl\u00e4ggningen invigd och GMP-certifierad, patent godk\u00e4nt i Europa och produktprojekten n\u00e4rmar sig klinisk fas\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\\\/\",\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2022 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2022-08-26T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2022 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2022 - Nanexa AB","og_description":"Pilotanl\u00e4ggningen invigd och GMP-certifierad, patent godk\u00e4nt i Europa och produktprojekten n\u00e4rmar sig klinisk fas","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"3 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\/","name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2022 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2022-08-26T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-delarsrapport-for-januari-juni-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar del\u00e5rsrapport f\u00f6r januari-juni 2022"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6535","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6535"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}